ASCO GU 2023 - Results from #120

Viewing 121-140 of 190 articles

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

ASCO GU 2023: Results of a Multicenter, Randomized, Phase 3 Trial of Trimodality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Long- Versus Short-Term ADT for Localized High-Risk Prostate Cancer (TRIP/TRIGU0907)

ASCO GU 2023: Efficacy and Safety of Abiraterone Acetate plus Prednisone and ADT +/- Docetaxel in Older Patients (≥70 Years), with De Novo mCSPC, Compared to Younger Patients (70 Years): The PEACE-1 Trial

ASCO GU 2023: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis

ASCO GU 2023: Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories

ASCO GU 2023: 10-Year Efficacy and Co-Morbidity Outcomes of a Phase III Randomised Trial of Conventional vs. Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP; CRUK/06/016)

ASCO GU 2023: New Targets, New Concepts for Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2023: How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2023: Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2023: Comparative Transcriptomic Analysis of DNA-Damage Response and Androgen Receptor Pathway Activity Between Biopsy and Radical Prostatectomy Specimens Before and After Pre-Operative Real-Time MRI-Guided Stereotactic Body Radiotherapy

ASCO GU 2023: Comparison of ctDNA Between African American and Caucasian Patients with CRPC Post Abiraterone And/or Enzalutamide

ASCO GU 2023: Circulating Tumor DNA Identifies Homologous Recombination Deficiency in Bone-Predominant mCRPC Prior to Radium-223 Therapy

ASCO GU 2023: Detection of Emergent Neuroendocrine Prostate Cancer in Liquid Biopsies Associated with Inferior Survival and Treatment Resistance

ASCO GU 2023: Factors Related to Men’s Experience with Prostate Cancer Germline Testing

ASCO GU 2023: PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

ASCO GU 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC

ASCO GU 2023: The Androgen Receptor Remains the Main Driver of Disease: Towards Third-Generation Inhibitors?

ASCO GU 2023: Implementing 18F-DCFPyL PET in Clinical Practice: Prescribing Patterns and Utilization at a Large Academic Center

ASCO GU 2023: Real-World Use of Darolutamide, Enzalutamide, and Apalutamide for Non-Metastatic Castration-Resistant Prostate Cancer (DEAR)

1
2
3
4
5
6
7
8
9
10